HIMS Earnings Preview: Will The Stock Rebound After 25% Drop?
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...
FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...
Why Novo Nordisk A/S (NVO) Surged On Friday?
We recently published a list of Five Chinese Firms Dominate Friday’s Top 10 Gainers. In this article, we are going to take a ...
Lilly, Novo dominance to continue as TD Cowen lifts 2030 GLP-1 sales forecast by 38%
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
The Pharma Letter14h
FDA says semaglutide shortage is resolved
The US Food and Drug Administration (FDA) said it has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is now resolved.
Altoona Mirror6h
Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...
FDA declares end to Wegovy and Ozempic shortage
The Food and Drug Administration announced Friday it had officially declared an end to the nationwide shortage of Ozempic and Wegovy, medications used for diabetes and weight loss.The agency first ...